Credit Suisse analyst Matt Miksic initiated Edwards Lifesciences with an Outperform rating and a price target of $188 as part of his broader research note on Medical Supplies and Devices partially titled "No Disruption, No Alpha", calling the stock stock his top pick for exposure to Structural Heart medicine. The analyst anticipates the company to post "solid double-digit top-line growth in 2020-2022, and improving revenue mix and gross margins" with added tailwinds coming from his forecast for the addressable Transcatheter aortic valve replacement market to double in 2019.

Sees Q2 revenue $1.62B-$1.7B, consensus $1.64B.

Reports Q1 revenue $1.6B, consensus $1.57B. "Edwards is positioned to extend our leadership and deliver sustainable growth as a result of the strategic investments we have made across our transcatheter platforms to address the large and growing needs of patients impacted by aortic, mitral and tricuspid disease. We are pleased with our total company performance with first quarter sales growth of 10% as more patients were treated with our innovative therapies," said Bernard Zovighian, CEO. "This encouraging start to the year supports our increased 2024 sales guidance. Looking beyond 2024, we remain confident in Edwards' innovation-driven strategy, led by new indications, differentiated technologies and strategic adjacencies for addressing the significant unmet needs of structural heart disease patients."

Pre-earnings options volume in Edwards Lifesciences is 5.5x normal with puts leading calls 10:7. Implied volatility suggests the market is anticipating a move near 4.8%, or $4.27, after results are released. Median move over the past eight quarters is 6.3%.